You are here

Articles

CML: Mechanisms of Resistance & Treatment: Elias Jabbour, Sameer A. Parikh, Hagop Kantarjian, Jorge Cortes, published online 20 October 2011.

published: 16 November 2011

Vaxil Biotherapeutics: 'Cancer' vaccine in phase1/11 clinical trials.

published: 15 November 2011

24 month follow up- Nilotinib in AP CML following imatinib resistance/intolerance

published: 13 November 2011

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

published: 11 November 2011

STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML

published: 11 November 2011

Nilotinib vs imatinib in ph+CML: 24-month data from phase 3 ENESTnd trial

published: 3 November 2011

SCT- CMV Virus vs Leukaemia Effect?

published: 10 October 2011

Lancet Article: nilotinib continues to our perform imatinib

published: 24 September 2011

Ariad's TKI: ponatinib- PACE, a phase 11 clinical trial

published: 24 August 2011

ecancerTV interviews Hagop Kantarjian of MDACC.

published: 6 August 2011

UK National CML Patinet/Carer Seminar- Cardiff 12th November 2011

published: 2 August 2011

Carcinogenicity of radiofrequency electromagnetic fields

published: 25 June 2011

CytRx- Bafetinib (INNO-406) bcr/abl + Lyn inhibitor

published: 24 June 2011

Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet

published: 17 June 2011

NICE: CML patients attend meeting and protest outside

published: 10 June 2011

NICE? I don't think so!

published: 11 May 2011

Letter Templates to send to MP's- 4 versions

published: 11 May 2011

'Write To Them'

published: 10 May 2011

CML Support Group Press statement: NICE Appraisal for imatinib resistant CML. 06/05/2011

published: 6 May 2011

Minimal cross-intolerance with nilotinib

published: 3 May 2011